UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 161

Sortiert nach

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Journal of clinical oncology, 2019-04, Vol.37 (11), p.912-922

2019

Link zum Volltext

Verfügbarkeit prüfen

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

The lancet oncology, 2021-06, Vol.22 (6), p.790-800

2021

Link zum Volltext

Verfügbarkeit prüfen

Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection

The New England journal of medicine, 2016-10, Vol.375 (17), p.1699-1701

2016

Link zum Volltext

Verfügbarkeit prüfen

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Journal of clinical oncology, 2017-02, Vol.35 (5), p.544-551

2017

Link zum Volltext

Verfügbarkeit prüfen

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Blood, 2021-05, Vol.137 (19), p.2634-2645

2021

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Clinical cancer research, 2019-12, Vol.25 (23), p.6986-6994

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy

British journal of haematology, 2020-10, Vol.191 (2), p.194-206

2020

Link zum Volltext

Verfügbarkeit prüfen

FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study

British journal of haematology, 2021-02, Vol.192 (3), p.504-513

2021

Link zum Volltext

Verfügbarkeit prüfen

Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology

British journal of haematology, 2013-10, Vol.163 (2), p.168-181

2013

Link zum Volltext

Verfügbarkeit prüfen

Guidelines for the first line management of classical Hodgkin lymphoma

British journal of haematology, 2014-07, Vol.166 (1), p.34-49

2014

Link zum Volltext

Verfügbarkeit prüfen

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Haematologica (Roma), 2024-04, Vol.109 (4), p.1184-1193

2024

Link zum Volltext

Verfügbarkeit prüfen

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

British journal of haematology, 2021-02, Vol.192 (3), p.e84-e87

2021

Link zum Volltext

Verfügbarkeit prüfen

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trial

British journal of haematology, 2016-11, Vol.175 (4), p.668-672

2016

Link zum Volltext

Verfügbarkeit prüfen

Cerebrospinal fluid leak after bone marrow biopsy

British journal of haematology, 2018-02, Vol.180 (3), p.319-319

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

European journal of cancer (1990), 2016-02, Vol.54, p.11-17

2016

Link zum Volltext

Verfügbarkeit prüfen

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Blood advances, 2020-08, Vol.4 (16), p.3850-3852

2020

Link zum Volltext

Verfügbarkeit prüfen

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination

British journal of haematology, 2023-09, Vol.202 (6), p.1091-1103

2023

Link zum Volltext

Verfügbarkeit prüfen

Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies

British journal of haematology, 2021-12, Vol.195 (5), p.706-709

2021

Link zum Volltext

Verfügbarkeit prüfen

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Clinical lymphoma, myeloma and leukemia, 2022-05, Vol.22 (5), p.e335-e339

2022

Link zum Volltext

Verfügbarkeit prüfen

Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma

Journal of clinical oncology, 2011-12, Vol.29 (35), p.4696-4701

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial

British journal of haematology, 2021-03, Vol.192 (6), p.1015-1019

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(158)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Englisch
(161)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(64)
Science & Technology
(64)
Humans
(57)
Hematology
(47)
Adult
(35)
Female
(35)
Middle Aged
(32)
Male
(31)
Aged
(29)
Lymphoma
(25)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(22)
Treatment Outcome
(20)
Young Adult
(18)
Biological And Medical Sciences
(17)
Oncology
(17)
Aged, 80 And Over
(16)
Medical Sciences
(15)
Hematologic And Hematopoietic Diseases
(14)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(14)
Lymphoma, Large B-Cell, Diffuse - Drug Therapy
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(52)
British Journal Of Haematology
(39)
Clinical Lymphoma, Myeloma And Leukemia
(11)
Journal Of Clinical Oncology
(6)
Leukemia & Lymphoma
(6)
Blood Advances
(5)
Clinical Cancer Research
(3)
Eclinicalmedicine
(3)
Leukemia
(3)
Annals Of Hematology
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Remission of Follicular Lymphoma after Treatment for Hepatitis C Virus Infection

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Clinical outcomes and risk factors for severe COVID‐19 in patients with haematological disorders receiving chemo‐ or immunotherapy

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

FDG‐PET/CT after two cycles of R‐CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study

Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology

Guidelines for the first line management of classical Hodgkin lymphoma

Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma

The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single‐centre series

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trial

Cerebrospinal fluid leak after bone marrow biopsy

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy

Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination

Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma

Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial

Suchergebnisse filtern